Amicus Opens Philly CoE

Amicus Therapeutics has opened the company’s Global Research and Gene Therapy Center of Excellence in uCity Square in Philadelphia, PA, to advance its portfolio of rare disease gene therapy programs.
 
In 2019, Amicus and the University of Pennsylvania announced a major expansion of their gene therapy collaboration, which provides Amicus with disease-specific worldwide rights to Penn’s next generation gene therapy technologies from the Wilson Lab for the majority of lysosomal storage disorders, as well as twelve additional more prevalent rare diseases including Rett Syndrome, Angelman Syndrome and select other muscular dystrophies.
 
"This is a remarkable advancement in the history of Amicus and further strengthens our great collaboration with Dr. Jim Wilson and the Gene Therapy Center at Penn," said John Crowley, chairman and chief executive officer, Amicus Therapeutics. "Philadelphia is a magnet for talent in gene therapy and an engine for innovation. This new global research center located in the ‘cradle of liberty’ will become part of the ‘cradle of cures’ as we move many gene therapy programs forward toward patients in need. With exclusive global rights to 50 rare diseases in collaboration with Dr. Wilson’s team we hope to be able to alleviate an enormous amount of human suffering with the great science work that will be done in this new facility."
 
The 75,000 square foot center is located on the top three floors of the new building at 3675 Market Street and consists of office and state-of-the-art laboratories. It will ultimately house approximately 200 researchers and drug developers focused exclusively on gene therapies.

Register as Visitor to CPhI China 2020!

-----------------------------------------------------------------------
Editor's Note:

En-CPhI.CN is a vertical B2B online trade platform serving the pharmaceutical industry,

for any copyright disputes involved in the articles,

please email: Julia.Zhang@imsinoexpo.com to motify or remove the content.